Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Invivyd (IVVD)
NASDAQ:IVVD
Invivyd (IVVD) Stock Price & Analysis
198 Followers
IVVD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.05 - $5.20
Previous Close$1.2
Volume330.69K
Average Volume (3M)755.65K
Market Cap
$143.18M
Enterprise Value-$55.30M
Total Cash (Recent Filing)$200.64M
Total Debt (Recent Filing)$2.17M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Sep 16, 2024EPS Estimate
-$0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares Outstanding119,315,787
10 Day Avg. Volume313,478
30 Day Avg. Volume755,653
Standard Deviation0.44
R-Squared0.00919
Alpha0.00383
Financial Highlights & Ratios
Price to Book (P/B)0.83
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.33
Forecast
1Y Price Target
$11.33Price Target Upside930.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Invivyd News
PremiumCompany Announcements
Invivyd Announces Executive Leadership Shakeup and Strategic FDA Alignment
Bulls Say, Bears Say
Bulls Say
Phase 3 DataVYD222 produced high serum virus neutralizing antibody titer levels in immunocompromised participants with a favorable safety profile including no study drug-related serious adverse events, supporting an immunobridging approach for a high probability of success in Phase 3 and subsequent FDA approval for EUA.
Product LaunchTimothy Lee takes over as Chief Commercial Officer to further support the launch of Pemgarda, leveraging his extensive commercial experience leading product launches for Alexion, Biohaven, and Amylyx.
Regulatory ProgressInvivyd continues to make progress on establishing a defined regulatory pathway to expedite the review of future monoclonal antibodies (mAbs) for the prevention and treatment of symptomatic COVID-19.
Bears Say
Clinical DevelopmentRisks include clinical development risk tied to VYD222 as well as additional emerging candidates, competitor risk in relevant therapeutic areas, and commercialization risk.
LeadershipJeremy Gowler (interim CEO) will be stepping down.
Safety ConcernsBoxed warning for anaphylaxis, which was reported in 4/623 participants.
---
Ownership Overview
78.01% Insiders
7.24% Mutual Funds
6.00% Other Institutional Investors
8.75% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IVVD FAQ
What was Invivyd’s price range in the past 12 months?
Invivyd lowest stock price was $1.05 and its highest was $5.20 in the past 12 months.
What is Invivyd’s market cap?
Currently, no data Available
When is Invivyd’s upcoming earnings report date?
Invivyd’s upcoming earnings report date is Sep 16, 2024 which is in 75 days.
How were Invivyd’s earnings last quarter?
Invivyd released its earnings results on May 09, 2024. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.467 by $0.087.
Is Invivyd overvalued?
According to Wall Street analysts Invivyd’s price is currently Undervalued.
Does Invivyd pay dividends?
Invivyd does not currently pay dividends.
What is Invivyd’s EPS estimate?
Invivyd’s EPS estimate is -$0.36.
How many shares outstanding does Invivyd have?
Invivyd has 119,315,790 shares outstanding.
What happened to Invivyd’s price movement after its last earnings report?
Invivyd reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.467. Following the earnings report the stock price went down -6.612%.
Which hedge fund is a major shareholder of Invivyd?
Among the largest hedge funds holding Invivyd’s share is Maverick Capital ltd. It holds Invivyd’s shares valued at 52M.
---
Invivyd Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.33 (930.00% Upside)
$11.33 (930.00% Upside)
Blogger Sentiment
Bullish
IVVD Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 3.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $186.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
14.28%
12-Months-Change
Fundamentals
Return on Equity
-81.87%
Trailing 12-Months
Asset Growth
-38.54%
Trailing 12-Months
Company Description
Invivyd
Adagio Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company's lead product candidate, ADG20 is developed for the treatment and prevention of coronavirus disease 2019, or COVID-19, the disease caused by the virus SARS-CoV-2 and its variants.
---
IVVD Company Deck
---
IVVD Earnings Call
Q1 2024
0:00 / 0:00
---
IVVD Stock 12 Month Forecast
Average Price Target
$11.33
▲(930.00% Upside)
Technical Analysis
Best Analysts Covering IVVD
1 Year
1 Year Success Rate
2/10 ratings generated profit
1 Year Average Return
-25.54%
reiterated a buy rating last month
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -25.54% per trade.
---